Please wait while the transcript is being prepared...
0:00
Hi, my
name is Yaning Wang.
I'll present the pharmacometrics
in pain management
on behalf of the author list.
0:10
First of all, I would like to
point out that opinions expressed
in this presentation
are those of the authors
and may not necessarily
be consistent with some
of the current product
development standards
of the regulatory agencies.
To obtain the most current standards
or advice for drug development,
for opioids or any
products being developed,
the readers should contact
the regulatory agency.
0:37
In this talk, I will start with
the background about pain and pain
management, followed by
a general introduction
of the modeling in
chronic and acute pain.
Then I will talk about the
application of pharmacometrics
in clinical patient care
and opioid treatments.
Then I will use two case studies to
demonstrate how pharmacometrics can
be applied in the regulatory
decision making process.
And finally, I will
finish with a summary.
1:05
Pain is a dynamic phenomenon.
It is defined by the International
Association for the Study of Pain
as unpleasant sensory and emotional
experience associated with actual
or potential tissue damage or is
described in terms of such damage.
The sensation results
from nerve impulses
reaching the cerebral cortex
via specific neural pathways
and is modulated at all
levels of peripheral
and central nervous systems.
The prevalence of chronic pain is
high in industrialized countries.
It has been estimated that
about 100 million adults suffer
from chronic pain in the United
States alone, with treatment costs
and loss of productivity added up
to 635 billion per year. Globally,
about 20% of adults suffer
from pain and 10% of adults
become new chronic pain
patients each year.
Life quality of a
patient with chronic pain
is largely compromised because
of the persistent nature
of the symptom.
